Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ramelteon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A known ✓ | P48039 | 20/20 | 1.00 |
| ▸ | MTNR1B known ✓ | P49286 | 20/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Ramelteon SCHEMBL1566122 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Ramelteon SCHEMBL29380213 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| (R)-Ramelteon SCHEMBL29827337 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| (R)-Ramelteon SCHEMBL338730 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1566589 | 0.91 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1567007 | 0.88 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1567415 | 0.88 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL3065294 | 0.87 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL13985044 | 0.86 | MTNR1A (0.76) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1612991 | 0.85 | MTNR1A (0.78) | MTNR1AMTNR1BABCB11SIGMAR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6138 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2026-03-31 | — | — | US | claimed |
| US-12558358-B2 | N-(furan-2-ylmethyl)-7H-purin-6-amine for treatment of circadian rhythm diseases, disorders and dysfunctions | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2026-02-24 | — | — | US | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4683627-A1 | AMELIORATION OF DRUG-DRUG INTERACTIONS | Ontrack Therapeutics Limited (GB) | 2026-01-28 | — | — | EP | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| EP-4635514-A2 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | The Brigham & Women's Hospital, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-1100508-B1 | PHARMACEUTICAL COMBINATION COMPRISING A TRICYCLIC COMPOUND AND AT LEAST ONE OF ZOLPIDEM, ZOPICLONE AND BROTIZOLAM FOR TREATING OR PREVENTING SLEEP DISORDERS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-08-27 | — | — | EP | claimed |
| EP-1214944-A1 | PERCUTANEOUS ABSORPTION AGENTS | Takeda Chemical Industries, Ltd. (JP) | 2002-06-19 | — | — | EP | claimed |
| EP-0885210-B1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-06-12 | — | — | EP | claimed |
| EP-1206943-A1 | MATRIX ADHERING TO NASAL MUCOSA | Takeda Chemical Industries, Ltd. (JP) | 2002-05-22 | — | — | EP | claimed |
| US-6348485-B1 | ramelteon and one of zolpidem, zopiclone, brotizolam and triazolam | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-02-19 | — | — | US | claimed |
| EP-1100508-A2 | PHARMACEUTICAL COMBINATION COMPRISING A TRICYCLIC COMPOUND AND AT LEAST ONE OF ZOLPIDEM, ZOPICLONE AND BROTIZOLAM FOR TREATING OR PREVENTING SLEEP DISORDERS | Takeda Chemical Industries, Ltd. (JP) | 2001-05-23 | — | — | EP | claimed |
| US-6034239-A | BINDIG TO MELATONIN RECEPTORS; SLEEP DISORDERS; GLANDULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-07 | — | — | US | claimed |
| WO-1999063977-A2 | PHARMACEUTICAL COMBINATION COMPRISING A TRICYCLIC COMPOUND AND AT LEAST ONE OF ZOLPIDEM, ZOPICLONE, TRIAZOLAM AND BROTIZOLAM FOR TREATING OR PREVENTING SLEEP DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-16 | — | — | WO | claimed |
| EP-0885210-A1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1998-12-23 | — | — | EP | claimed |
| WO-1997032871-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-12 | — | — | WO | claimed |